

## GASTROINTESTINAL (GI) MEDICINES

### MARKETED PRODUCTS

**Nexium** (esomeprazole) is the first proton pump inhibitor (PPI) for the treatment of acid-related diseases to offer clinical improvements over other PPIs and other treatments.

**Losec/Prilosec** (omeprazole) was the first PPI, and is used for the short-term and long-term treatment of acid-related diseases.

**Entocort** (budesonide) is a locally acting corticosteroid for the treatment of inflammatory bowel disease (IBD) with better tolerability than other corticosteroids and greater efficacy than aminosalicyclic acid medicines.

### 2007 IN BRIEF

- > Sales of **Nexium** down 2% to \$5.2 billion.
- > **Losec/Prilosec** sales of over \$1 billion with sales growth in Japan and China. Overall sales down 20%.
- > European Patent Office rulings that the European process patent for **Nexium** and the European patent for the Multiple Unit Pellet (MUPS) formulations of **Losec** and **Nexium**, which expire in 2015, are valid in amended form.
- > Patent litigation continuing in the US against generic manufacturers following abbreviated new drug applications relating to **Nexium**.

### PERFORMANCE

	2007			2006			2005	2007 compared to 2006		2006 compared to 2005	
	Sales \$m	Growth underlying \$m	exchange effects \$m	Sales \$m	Growth underlying \$m	exchange effects \$m		Growth underlying %	Growth reported %	Growth underlying %	Growth reported %
<b>Nexium</b>	5,216	(104)	138	5,182	555	(6)	4,633	(2)	1	12	12
<b>Losec/Prilosec</b>	1,143	(277)	49	1,371	(266)	(15)	1,652	(20)	(17)	(16)	(17)
Other	84	2	4	78	8	-	70	3	8	11	11
<b>Total</b>	<b>6,443</b>	<b>(379)</b>	<b>191</b>	<b>6,631</b>	<b>297</b>	<b>(21)</b>	<b>6,355</b>	<b>(6)</b>	<b>(3)</b>	<b>4</b>	<b>4</b>

### PIPELINE

Compound	Mechanism	Areas under investigation	Phase			Estimated filing date		
			I	II	III	Europe	US	
<b>NCEs</b>								
AZD3355	inhibitor of transient lower oesophageal sphincter relaxations (TLESR)	GERD	■	■			2011	2011
AZD2066	metabotropic glutamate receptors subtype 5	GERD		■				
AZD1386	vanilloid receptor 1 antagonist	GERD		■				
<b>Line extensions</b>								
<b>Nexium</b>	proton pump inhibitor	peptic ulcer bleeding	■	■	■		2Q 2008	2Q 2008
<b>Nexium</b> sachet formulation	proton pump inhibitor	GERD	■	■	■		Approved <sup>1</sup>	Launched
<b>Nexium</b> low dose aspirin combination	proton pump inhibitor	low dose aspirin associated peptic ulcer	■	■	■			1H 2009
<b>Nexium</b>	proton pump inhibitor	extra-oesophageal reflux disease	■	■			2H 2009 <sup>2</sup>	2H 2009 <sup>2</sup>

<sup>1</sup> Approved by EU reference member state, mutual recognition procedure ongoing.

<sup>2</sup> Project Extraesophageal reflux disease (reflux asthma) will be completed but will not result in a regulatory filing.

For discontinued projects see page 30.